11 December 2025 - Top Stories

Recent global research indicates that hidradenitis suppurativa (HS) affects approximately 1 in 100 people, including in Australia. This challenges previous perceptions of HS as a rare condition and underscores the need for health systems to improve diagnosis and management. Despite its prevalence, HS remains underdiagnosed and undertreated, often leading to significant psychological and social impacts for patients.

Advances in healthtech are evident in the development of AI tools such as GigaTIME, which analyses tumour microenvironments across multiple cancer types. By generating virtual immunofluorescence images from standard slides, this technology enables large-scale research, revealing over 1,200 significant protein links related to tumour progression and survival. Such innovations could accelerate personalised cancer treatments and research efficiency.

In Australia, a trial using the antidepressant sertraline shows promise in reducing domestic violence reoffending among impulsive men. The double-blind study involving 630 participants found lower reoffending rates at 12 and 24 months for those on medication. This approach offers a potential new intervention method, integrating pharmacology with social support to address a national crisis.

Meanwhile, the health sector continues to grapple with safety and regulatory issues. Over 20 sunscreens have been recalled following concerns over SPF claims, highlighting the importance of reliable testing and labelling. Additionally, the Australian government is considering measures to curb high specialist fees, aiming to improve affordability and transparency in healthcare costs.

Other notable developments include the expansion of digital health initiatives and workforce strategies. Dedalus plans to create 100 new jobs in Ireland to bolster digital health infrastructure, while Australian GPs are increasingly involved in early childhood care and preventive services. Efforts to address GP shortages in Western Sydney and improve veteran support reflect ongoing priorities to strengthen primary care and community health services.

• Global HS prevalence highlights diagnostic gaps and care needs.
• AI models like GigaTIME enhance cancer research capabilities.
• Australian trials explore medication-based approaches to social issues.
• Sunscreen recall underscores testing reliability concerns.
• Workforce and digital health investments aim to improve access and quality.
• Policy shifts reflect a focus on affordability, safety, and inclusivity.